Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Nerl

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Leukemia|April 22, 2005
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemiaR F Schlenk, U Germing, F Hartmann, et al.
ACS Nano|May 14, 2015
Basal-Plane Functionalization of Chemically Exfoliated Molybdenum Disulfide by Diazonium SaltsKathrin C Knirsch, Nina C Berner, Hannah C Nerl, et al.
British Journal of Haematology|September 1, 2001
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study GroupM Hallek, B Schmitt, M Wilhelm, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Leukemia|January 27, 2006
Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment TrialR F Schlenk, S Fröhling, F Hartmann, et al.
Immunobiology|March 1, 1983
Statement on the nomenclature of human C4 allotypesG Mauff, C A Alper, Z Awdeh, et al.
Leukemia|October 3, 2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-CM C Müller, N Gattermann, T Lahaye, et al.
Leukemia|February 10, 2016
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IVM B Miranda, M Lauseker, M-P Kraus, et al.
Leukemia|July 30, 2003
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyureaR Hehlmann, U Berger, M Pfirrmann, et al.
Leukemia|October 15, 2015
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatmentA Gratwohl, M Pfirrmann, A Zander, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Leukemia|April 22, 2005
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemiaR F Schlenk, U Germing, F Hartmann, et al.
ACS Nano|May 14, 2015
Basal-Plane Functionalization of Chemically Exfoliated Molybdenum Disulfide by Diazonium SaltsKathrin C Knirsch, Nina C Berner, Hannah C Nerl, et al.
British Journal of Haematology|September 1, 2001
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study GroupM Hallek, B Schmitt, M Wilhelm, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Leukemia|January 27, 2006
Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment TrialR F Schlenk, S Fröhling, F Hartmann, et al.
Immunobiology|March 1, 1983
Statement on the nomenclature of human C4 allotypesG Mauff, C A Alper, Z Awdeh, et al.
Leukemia|October 3, 2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-CM C Müller, N Gattermann, T Lahaye, et al.
Leukemia|February 10, 2016
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IVM B Miranda, M Lauseker, M-P Kraus, et al.
Leukemia|July 30, 2003
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyureaR Hehlmann, U Berger, M Pfirrmann, et al.
Leukemia|October 15, 2015
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatmentA Gratwohl, M Pfirrmann, A Zander, et al.
Pageof 8